Homepage
Medication Guide
Indications of Encorafenib (Braftovi)
Encorafenib (Braftovi) is an oral kinase inhibitor that first received approval for marketing from the U.S. Food and Drug Administration (FDA) in 2018. Specifically designed to treat malignant tumors ...
504
Wednesday, November 12th, 2025, 09:33
How to Purchase Encorafenib (Braftovi)
Encorafenib (Braftovi) is an important kinase inhibitor drug used for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer with...
505
Tuesday, November 11th, 2025, 11:56
What Are the Side Effects of Trabectedin (Yondelis)?
Trabectedin (Yondelis) is an alkylating agent approved by the U.S. FDA in 2015 for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously received ...
505
Tuesday, November 11th, 2025, 11:43
Precautions for Using Trabectedin (Yondelis)
Trabectedin (Yondelis) is a new type of alkylating agent drug. Approved for marketing in the United States in 2015, it is specifically indicated for the treatment of patients with unresectable or meta...
507
Tuesday, November 11th, 2025, 11:37
How to Use Trabectedin (Yondelis)
Trabectedin (Yondelis) is an alkylating agent. First approved in the United States in 2015, it is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma ...
503
Tuesday, November 11th, 2025, 11:00
Indications for Trabectedin (Yondelis)
Trabectedin (Yondelis) is an injectable alkylating agent approved by the U.S. Food and Drug Administration (FDA) in 2015 for clinical treatment, specifically targeting certain types of soft tissue sar...
504
Tuesday, November 11th, 2025, 10:54
How to Purchase Trabectedin (Yondelis)
Trabectedin (Yondelis) is a new type of alkylating agent, indicated for patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously received anthracycline-containing reg...
506
Tuesday, November 11th, 2025, 10:46
What Are the Side Effects of Cobenfy (KarXT)?
Cobenfy (KarXT) is a drug approved by the U.S. FDA in 2024 for the treatment of schizophrenia in adults. As a fixed-dose combination of xanomeline (a muscarinic agonist) and trospium chloride (a musca...
504
Tuesday, November 11th, 2025, 10:43
Precautions for Using Cobenfy (KarXT)
Cobenfy (KarXT) is an innovative therapeutic drug for schizophrenia, approved in the United States in 2024 and specifically designed for adult patients with schizophrenia. This drug is a fixed-dose co...
505
Tuesday, November 11th, 2025, 10:40
How to Use Cobenfy (KarXT)
Cobenfy (KarXT) is an oral capsule formulation composed of xanomeline (a muscarinic agonist) and trospium chloride (a muscarinic antagonist). It was first approved in the United States in 2024 for the...
505
Tuesday, November 11th, 2025, 10:37
54 / 200
1996 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved